Ovarian Cancer Drugs Market Size and Forecast 2020 - 2030, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type, Drug Class, Distribution Channel, and Geography

The ovarian cancer drugs market size is expected to grow from US$ 2.1 billion in 2022 to US$ 3.8 billion by 2030. Factors such as the rising incidence of ovarian cancer propel the demand for therapeutic options thereby responsible for influential ovarian cancer drugs market growth.

Rising Incidence Of Ovarian Cancer Propel The Demand For Therapeutic Options Drives Market Growth

Ovarian cancer is the seventh most common cancer among women and the third most common gynecological malignancy after cervical cancer and endometrial (uterine) cancers. According to the World Ovarian Cancer Coalition report, 324,000 women are diagnosed with ovarian cancer, among which 207,000 die of the disease annually. Further, the majority of patients with ovarian cancer are diagnosed with advanced (locally advanced or metastatic) stage as there is no public health screening program available for early detection of ovarian cancer. Therefore, the rising incidence of ovarian cancer propels the demand for therapeutic options. The first-line therapy with a combination of debulking surgery and platinum-based chemotherapy is standard care for women newly diagnosed with advanced ovarian cancer. Also, the breakthrough options for the management of newly diagnosed ovarian cancer are therapeutic options such as approved PARP inhibitors, olaparib, rucaparib, and niraparib. The use of PARP inhibitors in the management of advanced ovarian cancer has emerged as an effective therapeutic option to improve clinical outcomes for patients suffering from the disease. For example, PARP inhibitors provide long-term efficacy and progression-free survival (PFS) for the newly diagnosed disease following a complete response (CR)to first, second, and third platinum-based chemotherapy. Therefore, significant product approvals for ovarian cancer treatment drugs will positively impact the ovarian cancer drugs market size.

Therefore, the aforementioned factors are increasing the demand for ovarian cancer drugs for disease management, facilitating the expansion of the market share.

Ovarian Cancer Market Trends

Combination Drug Therapy

Combination drug therapy intended for ovarian cancer will grow significantly in the coming years. Also, several medical research institutes are developing a novel combination drug to treat ovarian cancers. For example, in September 2023, Researchers at the Royal Marsden announced new drug combination therapy that proves effective for patients living with advanced ovarian cancer. The researchers tested combination drug therapy for low-grade serous ovarian cancer (LGSOC), which is a rare form of ovarian cancer that has a poor response rate to treatments. The clinical trial "RAMP-201 trial" was conducted by using the "avutometinib" drug with a combination of another drug, namely, "defactinib," for patients suffering from LGSOC. The interim clinical trial results reveal that 45% of the patients treated with the drug combination saw their tumors shrink significantly. Such satisfactory clinical results with combination therapy is almost twice as effective compared to the targeted drug therapy called "trametinib," a drug available in England that has a response rate of only 26%. Further, in January 2024, the FDA announced approval for "SH-105" for the treatment of patients with breast and ovarian cancer as a combination drug. Such clinical advancements and product approvals are important steps to improve access to and administration of drugs that will treat breast and ovarian cancer among women. Such clinical advancements present a lucrative opportunity for the manufacturers to bring innovative combination products into the global market.

Ovarian Cancer Drugs Market, by Type:

By type, the ovarian cancer drugs market is segmented into epithelial ovarian cancer, germ cell ovarian cancer, and stromal tumors. The epithelial ovarian cancer segment held the largest ovarian cancer drugs market share in 2022 and the same segment is anticipated to register the highest CAGR of 8.2% during the forecast period.

According to the Cancer Research UK report, epithelial ovarian cancer is the most common type of ovarian cancer. For example, about 90 out of 100 tumors of the ovary (90%) are epithelial. Therefore, fast drug product approvals is a key factor in treating epithelial ovarian cancer thereby responsible for influential segment growth for the forecast period 2020-2030. Also, patients with aggressive, late-stage ovarian cancer have limited treatment options. For instance, in November 2022, the Food and Drug Administration (FDA) announced approval for "mirvetuximab soravtansine-gynx," manufactured by Elahere ImmunoGen, Inc. for adult patients suffering from epithelial ovarian cancer. The "mirvetuximab soravtansine-gynx" is a recommended dose by the physician of 6mg/kg administered once every three weeks as an IV infusion for epithelial ovarian cancer suffering patients. Additionally, in January 2024, the FDA announced approval for fast-track designation (FTD) for "RC88," a mesothelin-targeting antibody-drug conjugate (ADC) for the treatment of patients with recurrent epithelial ovarian cancer.

Competitive Landscape and Key Companies:

Elli Lilly, AstraZeneca, GSK, Zielab, ImmunoGen (AbbVie), GeneTech (Roche), Vivesto, Allarity Therapeutics, Inc., Aeterna Zentaris, and Luye Pharma are the prominent companies in the ovarian cancer drugs market report. These companies focus on new technologies, upgrading existing products, and geographic expansions to meet the growing consumer demand worldwide.